DOP2017000001A - Forma polimórfica novedosa del clorhidrato de n-[2-(6-fluoro-1h-indol-3-il)etil]-3-(2,2,3,3-tetrafluoropropoxi)bencilamina para el tratamiento del alzhéimer - Google Patents

Forma polimórfica novedosa del clorhidrato de n-[2-(6-fluoro-1h-indol-3-il)etil]-3-(2,2,3,3-tetrafluoropropoxi)bencilamina para el tratamiento del alzhéimer

Info

Publication number
DOP2017000001A
DOP2017000001A DO2017000001A DO2017000001A DOP2017000001A DO P2017000001 A DOP2017000001 A DO P2017000001A DO 2017000001 A DO2017000001 A DO 2017000001A DO 2017000001 A DO2017000001 A DO 2017000001A DO P2017000001 A DOP2017000001 A DO P2017000001A
Authority
DO
Dominican Republic
Prior art keywords
tetrafluoropropoxi
bencilamine
novedous
etil
indol
Prior art date
Application number
DO2017000001A
Other languages
English (en)
Inventor
Kristine Birklund Andersen
Michael Harold Rock
Heidi Lopez De Diego
Frans Dennis Therkelsen
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58794010&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2017000001(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of DOP2017000001A publication Critical patent/DOP2017000001A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A UNA FORMA POLIMÓRFICA NOVEDOSA DEL CLORHIDRATO DE N-[2-(6-FLUORO-1H-INDOL-3-IL)ETIL]-3-(2,2,3,3-TETRAFLUOROPROPOXI)BENCILAMINA.
DO2017000001A 2014-07-04 2017-01-03 Forma polimórfica novedosa del clorhidrato de n-[2-(6-fluoro-1h-indol-3-il)etil]-3-(2,2,3,3-tetrafluoropropoxi)bencilamina para el tratamiento del alzhéimer DOP2017000001A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA201400369 2014-07-04

Publications (1)

Publication Number Publication Date
DOP2017000001A true DOP2017000001A (es) 2017-03-31

Family

ID=58794010

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2017000001A DOP2017000001A (es) 2014-07-04 2017-01-03 Forma polimórfica novedosa del clorhidrato de n-[2-(6-fluoro-1h-indol-3-il)etil]-3-(2,2,3,3-tetrafluoropropoxi)bencilamina para el tratamiento del alzhéimer

Country Status (41)

Country Link
US (1) US10071963B2 (es)
EP (1) EP3164385B1 (es)
JP (2) JP6643330B2 (es)
KR (1) KR102399374B1 (es)
CN (3) CN112961095A (es)
AP (1) AP2016009643A0 (es)
AR (1) AR101109A1 (es)
AU (1) AU2015282909B2 (es)
CA (1) CA2951794C (es)
CL (1) CL2017000002A1 (es)
CO (1) CO2017000019A2 (es)
CR (1) CR20160605A (es)
CY (1) CY1124594T1 (es)
DK (1) DK3164385T3 (es)
DO (1) DOP2017000001A (es)
EA (1) EA035894B1 (es)
EC (1) ECSP17000222A (es)
ES (1) ES2893619T3 (es)
GE (1) GEP20227368B (es)
HR (1) HRP20211596T8 (es)
HU (1) HUE056368T2 (es)
IL (1) IL249428B (es)
JO (1) JO3639B1 (es)
LT (1) LT3164385T (es)
MA (1) MA40345B1 (es)
MX (1) MX2016016895A (es)
MY (1) MY190715A (es)
NZ (1) NZ727251A (es)
PE (1) PE20170522A1 (es)
PH (1) PH12016502477B1 (es)
PL (1) PL3164385T3 (es)
PT (1) PT3164385T (es)
RS (1) RS62380B1 (es)
RU (1) RU2016151637A (es)
SG (1) SG11201610334XA (es)
SI (1) SI3164385T1 (es)
SV (1) SV2016005353A (es)
TN (1) TN2016000549A1 (es)
TW (1) TWI665188B (es)
UA (1) UA121547C2 (es)
WO (1) WO2016001398A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3333154A1 (en) 2016-12-07 2018-06-13 Sandoz Ag Crystalline form of a selective 5-ht6 receptor antagonist

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1379239B1 (en) 2001-03-29 2007-09-12 Eli Lilly And Company N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor
TW201139370A (en) * 2009-12-23 2011-11-16 Lundbeck & Co As H Processes for the manufacture of a pharmaceutically active agent
JO3459B1 (ar) * 2012-09-09 2020-07-05 H Lundbeck As تركيبات صيدلانية لعلاج مرض الزهايمر
CN105175307A (zh) 2014-11-18 2015-12-23 苏州晶云药物科技有限公司 Lu AE58054的盐酸盐晶型A及其制备方法和用途

Also Published As

Publication number Publication date
CR20160605A (es) 2017-04-24
CN112961094A (zh) 2021-06-15
KR20170023019A (ko) 2017-03-02
HRP20211596T8 (hr) 2022-03-04
GEP20227368B (en) 2022-03-25
SV2016005353A (es) 2017-03-23
PL3164385T3 (pl) 2021-12-20
JP6643330B2 (ja) 2020-02-12
CN112961095A (zh) 2021-06-15
TW201625525A (zh) 2016-07-16
EA201692485A1 (ru) 2017-05-31
BR112017000127A2 (pt) 2018-01-23
PH12016502477A1 (en) 2017-04-10
PT3164385T (pt) 2021-10-07
US10071963B2 (en) 2018-09-11
JO3639B1 (ar) 2020-08-27
PE20170522A1 (es) 2017-05-28
RU2016151637A (ru) 2018-08-08
KR102399374B1 (ko) 2022-05-17
DK3164385T3 (da) 2021-10-11
AP2016009643A0 (en) 2016-12-31
TN2016000549A1 (en) 2018-04-04
HRP20211596T1 (hr) 2022-01-07
IL249428A0 (en) 2017-02-28
CO2017000019A2 (es) 2017-05-31
CA2951794A1 (en) 2016-01-07
AR101109A1 (es) 2016-11-23
CA2951794C (en) 2023-03-07
EA035894B1 (ru) 2020-08-27
SI3164385T1 (sl) 2021-10-29
EP3164385A1 (en) 2017-05-10
MX2016016895A (es) 2017-04-27
WO2016001398A1 (en) 2016-01-07
UA121547C2 (uk) 2020-06-25
MA40345B1 (fr) 2021-10-29
AU2015282909A1 (en) 2017-01-05
RS62380B1 (sr) 2021-10-29
HUE056368T2 (hu) 2022-02-28
TWI665188B (zh) 2019-07-11
IL249428B (en) 2019-10-31
CY1124594T1 (el) 2022-07-22
US20170152227A1 (en) 2017-06-01
SG11201610334XA (en) 2017-01-27
NZ727251A (en) 2023-06-30
MY190715A (en) 2022-05-12
JP2017519829A (ja) 2017-07-20
LT3164385T (lt) 2021-10-11
JP2020059724A (ja) 2020-04-16
EP3164385B1 (en) 2021-09-08
ES2893619T3 (es) 2022-02-09
PH12016502477B1 (en) 2017-04-10
AU2015282909B2 (en) 2019-02-07
CN106458889A (zh) 2017-02-22
ECSP17000222A (es) 2017-02-24
RU2016151637A3 (es) 2019-01-28
CL2017000002A1 (es) 2017-06-23
MA40345A (fr) 2021-04-28

Similar Documents

Publication Publication Date Title
CL2019002304A1 (es) Compuestos para el tratamiento del cáncer.
MA40551A (fr) Composés actifs envers des bromodomaines
CL2016002255A1 (es) Inhibidores de c5a para el tratamiento de la neumonía viral
MX2016011160A (es) Tratamiento de afecciones asociadas con la hiperinsulinemia.
MA41140A (fr) Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg
CY1122264T1 (el) Ppar ενωσεις για χρηση στην αντιμετωπιση των ινωτικων νοσων
IL250038A0 (en) 4,5 - dehydroisoxazole derivatives used as nampt inhibitors
CL2018001502A1 (es) Procedimiento para el tratamiento de efluente acuoso.
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
ES1192835Y (es) Maquina para el despedregado del terreno
FR3027494B1 (fr) Lacet de chaussure
DK3237407T3 (da) 3,5-diaminopyrazolkinasehæmmere
FR3019009B1 (fr) Lacet de chaussure
ITBA20140018A1 (it) Macchinario per la produzione di stracciatella
DOP2017000001A (es) Forma polimórfica novedosa del clorhidrato de n-[2-(6-fluoro-1h-indol-3-il)etil]-3-(2,2,3,3-tetrafluoropropoxi)bencilamina para el tratamiento del alzhéimer
ES1103806Y (es) Dispositivo para el secado integral del cuerpo
IT201700053882U1 (it) Mezzi per la produzione di calzature.
ES1183358Y (es) Maquina para despelonado de almendras.
IT201600112690A1 (it) Macchina per il trattamento di superfici pavimentate.
CO2017001201A2 (es) Composición blanqueadora
ES1187088Y (es) Calzado para condiciones adversas
ES1180258Y (es) Util para el tratamiento del estuco sintetico
ITUB20160795A1 (it) Forma per calzatura perfezionata.
MA42952A (fr) Dispositifs chaussants
ITMN20140007U1 (it) Calze per la stimolazione di zone del piede.